News & Updates

Show Multimedia Only

The next Berlin patient: 7th to join pool of HIV patients achieving sustained remission

13 Aug 2024 by

A new patient achieves sustained HIV remission – the seventh in the world – following stem cell therapy for blood cancer and after stopping antiretroviral therapy (ART), adding to the roster of individuals with HIV who are inching their way towards a potential cure.

13 Aug 2024

Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women

12 Aug 2024 by

In the interim analysis of the pivotal phase III PURPOSE 1 trial, twice-yearly subcutaneous lenacapavir, a first-in-class, high-potency HIV-1 capsid inhibitor, shows 100-percent efficacy and superiority to background HIV (bHIV*) incidence and daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF**) for pre-exposure prophylaxis (PrEP) in HIV-negative cisgender women.

12 Aug 2024

Score model predicts prognosis in older adults with pneumonia

10 Aug 2024

A new prediction score model identifies older patients with community-onset pneumonia who are nearing the end of life and need advance care planning (ACP) practices, reports a study.

10 Aug 2024

STI rates in high-risk populations curbed with doxycycline PrEP

09 Aug 2024 by

Pre-exposure prophylaxis (PrEP) with the antibiotic doxycycline helps to prevent sexually transmitted infections (STIs) in high-risk populations, including female sex workers and HIV-positive men who have sex with men (MSM), according to two small studies.

09 Aug 2024

Nirmatrelvir/ritonavir reduces risk of COVID-19 hospitalizations among outpatient elderly patients in SG

09 Aug 2024

A retrospective cohort study assessed the real-world effectiveness of nirmatrelvir/ritonavir in nonhospitalized elderly patients during transmission of Omicron sub-variants in Singapore.¹

09 Aug 2024

Dolutegravir plus lamivudine suppresses HIV without HBV reactivation

07 Aug 2024 by

The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.

07 Aug 2024

Long-acting CAB+RPV injections feasible in teens with HIV

06 Aug 2024 by

Virally suppressed adolescents living with HIV-1 who switched from daily oral to long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) every 8 weeks show an acceptable safety profile, with pharmacokinetics similar to adults, according to the week-48 results of the IMPAACT 2017 study.

06 Aug 2024

Original New Drug Application Approvals by US FDA (16-31 July 2024)

06 Aug 2024

New drug applications approved by US FDA as of 16-31 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

06 Aug 2024